Krishna Geethu, Thangaraju Sivakumar Palanimuthu, Dahale Ajit B, Subramanian Sarada
Department of Neurochemistry, National Institute of Mental Health & Neurosciences, Bengaluru, India.
Department of Psychiatry, National Institute of Mental Health & Neurosciences, Bengaluru, India.
J Alzheimers Dis Rep. 2024 Jan 9;8(1):1-7. doi: 10.3233/ADR-230156. eCollection 2024.
Blood tests are in need, in the clinical diagnosis of Alzheimer's disease (AD) as minimally invasive and less expensive alternatives to cerebrospinal fluid and neuroimaging methods. On these lines, single molecule array (Simoa) analysis of amyloid-β (Aβ), total tau (t-tau), phospho-tau (p-tau 181), and neurofilament L (NfL) in the plasma samples of AD subjects, healthy controls (HC), and non-AD subjects was conducted. Findings from this study suggest that a panel of multiple plasma biomarkers (NfL, Aβ, t-tau, and p-tau 181) combined with the clinical assessments could support differential diagnosis of AD and other dementias from healthy controls.
在阿尔茨海默病（AD）的临床诊断中，血液检测作为脑脊液和神经影像学方法的微创且低成本替代方案，很有必要。基于此，对AD患者、健康对照（HC）和非AD受试者的血浆样本进行了淀粉样β蛋白（Aβ）、总tau蛋白（t-tau）、磷酸化tau蛋白（p-tau 181）和神经丝轻链（NfL）的单分子阵列（Simoa）分析。该研究结果表明，一组多种血浆生物标志物（NfL、Aβ、t-tau和p-tau 181）与临床评估相结合，可辅助从健康对照中鉴别诊断AD和其他痴呆症。
